Bristol-Myers Squibb signs licensing deal with Novo Nordisk
For discovery research programme focused on autoimmune diseases
Bristol-Myers Squibb has reached an agreement with Novo Nordisk for an exclusive global licence to the Denmark-based company's discovery biologics research programme focused on modulating the innate immune system as a therapy for autoimmune diseases.
Financial terms of the agreement have not been disclosed.
Bristol-Myers Squibb said the agreement supports its long-standing commitment to immunoscience, a core therapeutic area.
The innate immune system is the body’s first line of defence against pathogens and responds to exogenous agents in an antigen non-specific way to stimulate an immediate protective response. Dysregulated innate immunity plays a critical role in the induction and pathogenesis of autoimmune diseases, the company said.
